Purpose: To describe the occurrence of bilateral primary uveal melanoma in 2 patients with mutation on the gene encoding BRCA1-associated protein 1 (BAP1). Methods: Retrospective chart review of patients with bilateral primary uveal melanoma and subsequent positive germline BAP1 mutation. Results: There were 2 patients with bilateral uveal melanoma and BAP1 germline positivity. Neither patient demonstrated oculodermal melanocytosis. Patient 1 underwent enucleation of his right eye (OD) at the age of 44 years for a 9.6-mm-thick choroidal melanoma. He returned 4 years later with a 10.0-mm-thick choroidal melanoma in his left eye (OS) and was treated with plaque radiotherapy. He had a strong family history of cancer, and clinical testing for germline BAP1 mutation identified a pathogenic mutation in BAP1. At the 18-month follow-up, visual acuity was 20/200 OS without evidence of systemic metastasis. Patient 2 initially presented at age 54 years with extensive, diffuse iris melanoma OD, initially treated with plaque radiotherapy, but local recurrence after 3 years necessitated enucleation. Four years later, a 6.0-mm-thick ciliary body melanoma OS was found and successfully treated with plaque radiotherapy. Clinical testing for germline BAP1 mutation identified a pathogenic mutation in BAP1. At the 8-year follow-up, visual acuity was 20/40 OS without evidence of local recurrence or systemic metastasis. The patient expired secondary to an unrelated brain infarction. Conclusion: Bilateral uveal melanoma is exceedingly rare. Patients with bilateral uveal melanoma, especially when coincident with remote systemic cancers or a family history of cancer, should be evaluated for germline BAP1 mutation. Lifelong monitoring for related systemic malignancies is advised.

1.
Shields
JA
,
Shields
CL
.
Intraocular tumors: An Atlas and Text
. 3rd ed.
Philadelphia (PA)
:
Lippincott Wolters Kluwer
;
2016
. pp.
45
59
.
2.
Rao
R
,
Pointdujour-Lim
R
,
Ganguly
A
,
Shields
CL
.
Multifocal choroidal melanoma in a patient with germline BRCA1-associated protein 1 mutation
.
Retin Cases Brief Rep
.
2018
;
12
(
1
):
1
4
.
[PubMed]
1935-1089
3.
Wiesinger
H
,
Phipps
GW
,
Guerry
D
 3rd
.
Bilateral melanoma of the choroid associated with leukemia and meningioma
.
Arch Ophthalmol
.
1959
Nov
;
62
(
5
):
889
93
.
[PubMed]
0003-9950
4.
Shammas
HF
,
Watzke
RC
.
Bilateral choroidal melanomas. Case report and incidence
.
Arch Ophthalmol
.
1977
Apr
;
95
(
4
):
617
23
.
[PubMed]
0003-9950
5.
Singh
AD
,
Shields
CL
,
Shields
JA
,
De Potter
P
.
Bilateral primary uveal melanoma. Bad luck or bad genes?
Ophthalmology
.
1996
Feb
;
103
(
2
):
256
62
.
[PubMed]
0161-6420
6.
Scott
JF
,
Vyas
R
,
Galvin
J
,
Gotow
E
.
Primary bilateral uveal melanoma: a population-based study and systematic review
.
Clin Exp Ophthalmol
.
2017
Dec
; [
Epub ahead of print
].
[PubMed]
1442-6404
7.
Turaka
K
,
Shields
CL
,
Shah
CP
,
Say
EA
,
Shields
JA
.
Bilateral uveal melanoma in an arc welder
.
Graefes Arch Clin Exp Ophthalmol
.
2011
Jan
;
249
(
1
):
141
4
.
[PubMed]
0721-832X
8.
Eide
N
,
Garred
Ø
,
Beiske
K
,
Fodstad
Ø
.
Bilateral uveal melanomas with different gene expression detected with 7 years interval
.
Acta Ophthalmol
.
2016
Feb
;
94
(
1
):
99
102
.
[PubMed]
1755-375X
9.
Furuta
M
,
Shields
CL
,
Uysal
Y
,
Shields
JA
.
Bilateral primary choroidal melanoma treated with bilateral plaque radiotherapy: a report of three cases
.
Eur J Ophthalmol
.
2006
Nov-Dec
;
16
(
6
):
879
82
.
[PubMed]
1120-6721
10.
Harbour
JW
,
Onken
MD
,
Roberson
ED
,
Duan
S
,
Cao
L
,
Worley
LA
, et al.
Frequent mutation of BAP1 in metastasizing uveal melanomas
.
Science
.
2010
Dec
;
330
(
6009
):
1410
3
.
[PubMed]
0036-8075
11.
Abdel-Rahman
MH
,
Pilarski
R
,
Cebulla
CM
,
Massengill
JB
,
Christopher
BN
,
Boru
G
, et al.
Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers
.
J Med Genet
.
2011
Dec
;
48
(
12
):
856
9
.
[PubMed]
0022-2593
12.
Rai
K
,
Pilarski
R
,
Cebulla
CM
,
Abdel-Rahman
MH
.
Comprehensive review of BAP1 tumor predisposition syndrome with report of two new cases
.
Clin Genet
.
2016
Mar
;
89
(
3
):
285
94
.
[PubMed]
0009-9163
13.
Cebulla
CM
,
Binkley
EM
,
Pilarski
R
,
Massengill
JB
,
Rai
K
,
Liebner
DA
, et al.
Analysis of BAP1 germline gene mutation in young uveal melanoma patients
.
Ophthalmic Genet
.
2015
Jun
;
36
(
2
):
126
31
.
[PubMed]
1381-6810
14.
Bhouri
L
,
Lumbroso
L
,
Levy
C
,
Dendale
R
,
Asselain
B
,
Plancher
C
, et al.
[Bilateral uveal melanomas. Five case reports]
.
J Fr Ophtalmol
.
2003
Feb
;
26
(
2
):
149
53
.
[PubMed]
0181-5512
15.
Shields
CL
,
Kaliki
S
,
Furuta
M
,
Mashayekhi
A
,
Shields
JA
.
Clinical spectrum and prognosis of uveal melanoma based on age at presentation in 8,033 cases
.
Retina
.
2012
Jul
;
32
(
7
):
1363
72
.
[PubMed]
0275-004X
16.
Buda
G
,
Romagnoli
MC
,
Galimberti
S
,
Figus
M
,
Papineschi
F
,
Nardi
M
, et al.
Simultaneous appearance of acute myeloid leukemia in a patient with bilateral primary uveal melanoma
.
Melanoma Res
.
2006
Oct
;
16
(
5
):
467
8
.
[PubMed]
0960-8931
17.
Gonder
JR
,
Shields
JA
,
Shakin
JL
,
Albert
DM
.
Bilateral ocular melanocytosis with malignant melanoma of the choroid
.
Br J Ophthalmol
.
1981
Dec
;
65
(
12
):
843
5
.
[PubMed]
0007-1161
18.
Honavar
SG
,
Shields
CL
,
Singh
AD
,
Demirci
H
,
Rutledge
BK
,
Shields
JA
, et al.
Two discrete choroidal melanomas in an eye with ocular melanocytosis
.
Surv Ophthalmol
.
2002
Jan-Feb
;
47
(
1
):
36
41
.
[PubMed]
0039-6257
19.
Den Otter
W
,
Koten
JW
,
Van der Vegt
BJ
,
Beemer
FA
,
Boxma
OJ
,
De Graaf
PW
, et al.
Hereditary cancer and its clinical implications: a view
.
Anticancer Res
.
1990
Mar-Apr
;
10
2B
:
489
95
.
[PubMed]
0250-7005
20.
Valencia
OM
,
Samuel
SE
,
Viscusi
RK
,
Riall
TS
,
Neumayer
LA
,
Aziz
H
.
The role of genetic testing in patients with breast cancer: a review
.
JAMA Surg
.
2017
Jun
;
152
(
6
):
589
94
.
[PubMed]
2168-6254
21.
Agaimy
A
,
Hartmann
A
.
[Hereditary renal tumors: more common than expected?]
.
Pathologe
.
2016
Mar
;
37
(
2
):
134
43
.
[PubMed]
0172-8113
22.
Masoomian
B
,
Shields
JA
,
Mashayekhi
A
,
Shields
CL
.
Growth of presumed choroidal nevus into melanoma over 4 years in BAP1 tumor predisposition syndrome.
In prep 170211, 171019
23.
Gupta
MP
,
Lane
AM
,
DeAngelis
MM
,
Mayne
K
,
Crabtree
M
,
Gragoudas
ES
, et al.
Clinical characteristics of uveal melanoma in patients with germline BAP1 mutations
.
JAMA Ophthalmol
.
2015
Aug
;
133
(
8
):
881
7
.
[PubMed]
2168-6165
24.
Carbone
M
,
Flores
EG
,
Emi
M
,
Johnson
TA
,
Tsunoda
T
,
Behner
D
, et al.
Combined genetic and genealogic studies uncover a large BAP1 cancer syndrome kindred tracing back nine generations to a common ancestor from the 1700s
.
PLoS Genet
.
2015
Dec
;
11
(
12
):
e1005633
.
[PubMed]
1553-7390
25.
Rai
K
,
Pilarski
R
,
Boru
G
,
Rehman
M
,
Saqr
AH
,
Massengill
JB
, et al.
Germline BAP1 alterations in familial uveal melanoma
.
Genes Chromosomes Cancer
.
2017
Feb
;
56
(
2
):
168
74
.
[PubMed]
1045-2257
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.